Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 701 - 750 out of 51,555

Document Document Title
WO/2016/056652A1
The purpose of the present invention is to provide a novel pharmacological composition with which it is possible to suppress the fibrosis of bone marrow associated with myelofibrosis. Examples of the present invention include: (1) a phar...  
WO/2016/055901A1
The present invention is directed at substituted amide compounds of formula (I), pharmaceutical compositions containing such compounds and the use of such compounds to reduce plasma lipid levels, such as LDL-cholesterol and triglycerides...  
WO/2016/054806A1
The present invention concerns compounds of formula I that inhibit HIF prolyl hydroxylase, their use for enhancing endogenous production of erythropoietin, and for treating conditions associated with reduced endogenous production of eryt...  
WO/2016/055797A3
There is herein provided valproic acid, or a pharmaceutically acceptable salt thereof, for use in treating or preventing a pathological condition associated with excess fibrin deposition and/or thrombus formation, wherein said treatment ...  
WO/2016/057932A1
This invention relates to compounds, compositions, and methods useful for reducing lactate dehydrogenase target RNA and protein levels via use of dsRNAs, e.g., Dicer substrate siRNA (DsiRNA) agents.  
WO/2016/056665A1
The purpose of the present invention is to provide a new drug that inhibits the formation of white blood cell extracellular traps. This invention provides: a white blood cell extracellular trap formation inhibitor that includes lactoferr...  
WO/2016/051609A1
This drug comprises a lanthanum carbonate hydrate which has a 90% cumulative diameter (D90) of 70μm or less and which is represented by La2(CO3)3⋅xH2O (in the formula, x represents a number 7-9). The drug does not have the problem of ...  
WO/2016/051221A1
Disclosed herein is a nutraceutical composition comprising dried Ziziphus mauritiana leaves, dried Lepidium sativum leaves, dried olive leaves at specific weight ratios and a specific amount of olive oil. The disclosed composition has be...  
WO/2016/053455A1
The present invention provides compounds of Formula (I) or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, wherein all the variables are as defined herein. These compounds are selective factor XIa inhibitors or du...  
WO/2016/045126A1
The present invention concerns compounds of formula I or a pharmaceutically acceptable salt thereof which inhibit HIF prolyl hydroxylase, their use for enhancing endogenous production of erythropoietin, and for treating conditions associ...  
WO/2016/045616A3
Provided are a pharmaceutical composition containing ginkgolide B and the blood platelet prostaglandin cyclooxygenase inhibitor aspirin, a method for preparation of said pharmaceutical composition, and a use thereof. When used together, ...  
WO/2016/046159A1
The invention relates to substituted oxopyridine derivatives and methods for the production thereof, as well as to the use thereof in the production of medicinal drugs for treating and/or preventing diseases, especially diseases of the c...  
WO/2016/049036A1
The present application relates to humanized antibodies that specifically bind to hepcidin and methods of using the humanized antibodies. Another aspect relates to humanized antibodies which bind hepcidin and regulate iron homeostasis. A...  
WO/2016/046166A1
The invention relates to substituted oxopyridine derivatives and methods for the production thereof, as well as to the use thereof in the production of medicinal drugs for treating and/or preventing diseases, especially diseases of the c...  
WO/2016/045128A1
The present invention concerns compounds of formula I or pharmaceutically acceptable salts thereof, which inhibit HIF prolyl hydroxylase, their use for enhancing endogenous production of erythropoietin, and for treating conditions associ...  
WO/2016/046158A1
The invention relates to substituted oxopyridine derivatives and methods for the production thereof, as well as to the use thereof in the production of medicinal drugs for treating and/or preventing diseases, especially diseases of the c...  
WO/2016/046157A1
The invention relates to substituted pyridobenzazepine and pyridobenzazocine derivatives and methods for the production thereof, as well as to the use thereof in the production of medicinal drugs for treating and/or preventing diseases, ...  
WO/2016/043251A1
 Provided are: a composition containing 96-99 area% of eicosapentaenoic acid alkyl ester, the composition having an arachidonic acid alkyl ester content of 0.7 area% or less, and an eicosapentaenoic-acid-alkyl-ester mono-trans isomer c...  
WO/2016/041192A1
Disclosed is a use of ligustilide, comprising a use of ligustilide to improve a therapeutic benefit of a stem cell, and a use of ligustilide and a stem cell treated therewith in a stem cell treatment. Treating the stem cell via the ligus...  
WO/2016/041256A1
A traditional Chinese medicine capable of activating blood and nourishing liver and kidney. The traditional Chinese medicine is prepared by using the following ingredients: 6 to 10 g of parasitic loranthus, 7 to 12 g of caulis spatholobi...  
WO/2016/038626A1
The present invention provides a pharmaceutical composition comprising Vitamin Kl and the process for preparation of the same. In particular, the present invention relates to stable injectable pharmaceutical compositions comprising a des...  
WO/2016/034108A1
Provided are a quinolinone compound, pharmaceutical composition thereof, and use of the compound or the pharmaceutical composition in drug preparation, the drug being used to prevent, manage, treat or relieve diseases related to HIF and/...  
WO/2016/034673A1
A compound of formula I wherein: n is 1 or 2: p is 0 or 1; R1 is optionally one or more halo or methyl groups; R2a and R2b are independently selected from the group consisting of: (i) F; (ii) H; (iii) Me; and (iv) CH2OH; R2c and R2d are ...  
WO/2016/034137A1
Disclosed are a compound of formula (I), a tautomer, an optical isomer or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition containing the above-mentioned compounds. The above-mentioned compounds have the activ...  
WO/2016/034145A1
A composition of (6S)-5-methyl tetrahydrofolic acid or a salt thereof as well as the preparation therefor and an application thereof. The content of the (6S)-5-methyl tetrahydrofolic acid or the salt thereof is not less than 98.0%, the c...  
WO/2016/034675A1
A compound of formula (I) wherein: R1 is optionally one or more halo or methyl groups; R2a and R2b are independently selected from the group consisting of: (i) F; (ii) H; (iii) Me; and (iv) CH2OH; R2c and R2d are independently selected f...  
WO/2016/035780A1
A novel pharmaceutical composition which can inhibit the formation of thrombi and emboli after the placement of a stent is provided. A pharmaceutical composition for inhibiting the formation of thrombi and emboli after the placement of a...  
WO/2016/036893A1
The present invention provides compounds of Formula (I) or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, wherein all the variables are as defined herein. These compounds are selective Factor XIa inhibitors or du...  
WO/2016/036807A1
Methods of accelerating the reconstitution of plasma powder by mixing the powder with small beads is disclosed. The beads can be, for example, glass and/or plastic resin beads having a diameter from about 2 mm to about 6 mm. The plasma p...  
WO/2016/034103A1
Disclosed are a substituted tetrahydrothieno pyridine derivative, a pharmaceutically acceptable acid salt, solvate or hydrate and a use thereof as shown by general formula (I), wherein R1, R2 and X are as defined in the description. Also...  
WO/2016/035790A1
The purpose of the present invention is to provide an erythrocyte function improving agent that has both high antioxidative effect and excellent migration ability to erythrocytes and is capable of effectively protecting erythrocytes agai...  
WO/2016/034617A1
The invention relates to the use of valproic acid, or one of the derivatives thereof, for correcting hepcidin abnormalities and the effects thereof, either those that lead to an iron overload or those that are associated with hepcidin de...  
WO/2016/029214A1
Use of a compound of formula (I): wherein A, X, Y, R1 and R2 as defined herein, in treating hereditary angioedema is disclosed. A composition containing the compounds, a polar organic solvent or a mixture thereof; and optionally a co-sol...  
WO/2016/028872A3
Factor IX/IXa variants and methods of use thereof are disclosed.  
WO/2016/029214A9
Use of a compound of formula (I): wherein A, X, Y, R1 and R2 as defined herein, in treating hereditary angioedema is disclosed. A composition containing the compounds, a polar organic solvent or a mixture thereof; and optionally a co-sol...  
WO/2016/026372A1
The present invention relates to thienocycloalkyl or thienoheterocyclic derivatives, a preparation method thereof and use thereof in medicine. In particular, the present invention relates to thienocycloalkyl or thienoheterocyclic derivat...  
WO/2016/024225A1
The present invention relates to a stable amorphous ticagrelor and a process for its preparation.  
WO/2016/021674A1
The purpose of the present invention is to provide a therapeutic and/or prophylactic agent, said agent targeting human Orai1, for transplant rejection, immunopathies, allergic diseases, inflammatory diseases, thrombi, cancers, etc. Provi...  
WO/2016/019847A1
The present invention relates to a fluorine substituted dabigatran ester derivative as indicated in formula (I), a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, and a use thereof in preparing medications for preven...  
WO/2016/021602A1
The purpose of the present invention is to provide a liquid immunity induction-promoting composition and a vaccine pharmaceutical composition that are capable of being universally used for liquid immunity induction against a variety of a...  
WO/2016/019848A1
A dabigatran thioester derivative as indicated in formula (I), a stereoisomer thereof, a pharmaceutically acceptable salt thereof, and a use thereof in preparing medications for preventing and treating thromboembolic diseases, X1, X2, R1...  
WO/2016/020345A1
The invention provides compositions and methods useful for the treatment and prevention of conditions associated with short telomere length.  
WO/2016/022656A1
This invention relates to methods of treating sickle cell disease with VLA-4 antagonists and methods for evaluating the responsiveness of patients having sickle cell disease to treatment with VLA-4 antagonists.  
WO/2016/019849A1
A dabigatran carboalkoxy derivative as indicated in formula (I), a stereoisomer thereof, a pharmaceutically acceptable salt thereof, and a use thereof in preparing medications for preventing and treating thromboembolic diseases, all subs...  
WO/2016/020080A1
Edoxaban is factor X inhibitor useful for the treatment or the prevention of thrombosis or embolism. A pharmaceutical composition comprising Edoxaban, or a pharmaceutically acceptable salt thereof, a water soluble vinylpyrrolidone polyme...  
WO/2016/019844A1
The present invention relates to a dabigatran cyclic ester derivative, as represented by formula (I), and a stereoisomer or pharmaceutically acceptable salt thereof, as well as a use thereof in the preparation of a pharmaceutical used fo...  
WO/2016/019846A1
The present invention relates to a dabigatran ester derivative, and a stereoisomer or pharmaceutically acceptable salt thereof, as well as a use thereof in the preparation of a pharmaceutical used for prevention and treatment of a thromb...  
WO/2016/022521A1
Provided are novel compounds of Formula (I): pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, which are liver X receptor modulators, and which are useful in the treatment of diseases and disorders assoc...  
WO/2016/016907A1
The present invention relates to novel polymorphs of (lS,2S,3R,5S)-3-[7-{[(lR,2S)-2- (3,4-difluorophenyl)cyclopropyl]amino}-5-(propylthio)-3H-[l, 2,3]-triazolo[4,5-d]pyrimidi yl]-5-(2-hydroxyethoxy)cyclopentane-l,2-diol represented by th...  
WO/2016/018702A1
The present invention provides a compound of Formula (I) (Formula(I)) and pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing thromboses, embolisms, hypercoag...  

Matches 701 - 750 out of 51,555